跳至主要内容
临床试验/NCT03582956
NCT03582956终止不适用

Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes

Yale University1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2019年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
23
试验地点
1
主要终点
Rate of Glucose Metabolism

研究概览

简要总结

The purpose of this study is to assess the effects of adiposity on resistance to insulin's ability to suppress hepatic glucose production and to stimulate peripheral glucose metabolism in adolescents with type 1 diabetes. In addition, this study will also examine the role of fatty liver disease on the insulin resistance of obesity in adolescents with type 1 diabetes.

详细描述

A major focus of this program of research will be directed at advancing the understanding of the metabolic consequences of obesity and puberty in adolescents with T1D. Thus, an innovative aspect of this research is that it will be the first to use these sophisticated metabolic techniques to examine the effects of obesity and hepatic steatosis on insulin sensitivity in pubertal adolescents with T1D; namely, the 2-step hyperinsulinemic euglycemic clamp with tracer enhancement, which will allow for definition of hepatic and peripheral insulin resistance, glycerol turnover, and glucose and fat oxidation. Further, a second novel aspect is that this will be the first study to utilize gold standard MRI methods to quantify and compare intrahepatic fat content in lean and obese adolescents with T1D. This will allow a global and more detailed understanding of the potential alterations of insulin's effects on key insulin sensitive tissues in youth that are impacted by both T1D and obesity. Furthermore, evaluation of biomarkers for insulin resistance and fatty liver disease in this population will be performed for the first time.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
12 Years 至 24 Years(Child, Adult)
性别
All
接受健康志愿者
是

入选标准

  • •All Participants:
  • •Clinical diagnosis of T1D
  • •Diabetes duration of at least 12 months
  • •Adolescents with T1D:
  • •Age 12-16 years
  • •BMI <75th for lean pediatric subjects, > 85th percentile for overweight/obese pediatric subjects;
  • •Tanner stage 2-5
  • •Parent able to provide written consent and participant able to provide assent
  • •Not meeting MRI safety criteria
  • •Claustrophobia that will prevent participation in the MRI
  • •Lean, young adults with T1D:
  • •Age 18-24 years
  • •BMI 18.5-24.9 kg/m2
  • •Able to provide written consent.

排除标准

  • •Use of adjunctive diabetes medications
  • •Weight loss medications within the past six months
  • •Current psychiatric disorders, including eating disorders (DSM-V criteria)
  • •Known liver disease other than nonalcoholic hepatic steatosis
  • •Females who are pregnant or lactating
  • •Anemia or another medical condition that precludes participation in the study

研究组 & 干预措施

Adolescent Typical

Other

Lean adolescents with T1D

干预措施: Euglycemic hyperinsulinemic clamp with tracer enhancement (Procedure)

Adolescent Overweight

Other

Adolescents with T1D and overweight/obesity

干预措施: Euglycemic hyperinsulinemic clamp with tracer enhancement (Procedure)

Young Adult

Other

Young adults with T1D with a euglycemic hyperinsulinemic clamp with tracer enhancement

干预措施: Euglycemic hyperinsulinemic clamp with tracer enhancement (Procedure)

结局指标

主要结局

Rate of Glucose Metabolism

时间窗: 120 minutes

Insulin function will be measured using a euglycemic hyperinsulinemic clamp procedure. A clamp measures insulin sensitivity. During the low does insulin phase, this reflects hepatic glucose metabolism, which is reported here. A higher glucose infusion rate number indicates more sensitivity to insulin; a lower number means more resistance to insulin.

Rate of Lipid Metabolism

时间窗: 120 minutes

Insulin function will be measured using a euglycemic hyperinsulinemic clamp procedure. A clamp measures insulin sensitivity. During the low dose insulin phase, glycerol turnover (rate of appearance) can reflect adipose specific insulin sensitivity, which is reported here. Insulin should suppress glycerol turnover. A higher number reflects more resistance to insulin; a lower number means more sensitivity to insulin.

Hepatic Sensitivity to Low Dose Insulin

时间窗: 120 minutes

Insulin function will be measured using a euglycemic hyperinsulinemic clamp procedure. A clamp measures insulin sensitivity. Insulin should suppress glucose production. Change of the glucose rate of appearance (which is reported here, and the glucose rate of appearance is measured here utilizing isotopic enrichment) during the low dose insulin phase reflects hepatic sensitivity to insulin. A greater degree of decline reflects more sensitivity to insulin; a smaller number means more resistance to insulin. This is calculated as the low dose insulin phase glucose rate of appearance minus the baseline phase glucose rate of appearance, divided by the basal phase glucose rate of appearance and multiplied x 100.

Peripheral Sensitivity to High Dose Insulin

时间窗: 240 minutes

Insulin function will be measured using a euglycemic hyperinsulinemic clamp procedure. A clamp measures insulin sensitivity. Insulin should suppress glucose production. Change of the glucose rate of appearance (which is reported here, and the glucose rate of appearance is measured here utilizing isotopic enrichment) during the high dose phase reflects peripheral sensitivity to insulin. A greater degree of decline reflects more sensitivity to insulin; a smaller number means more resistance to insulin. This is calculated as the high dose insulin phase glucose rate of appearance minus the baseline phase glucose rate of appearance, divided by the basal phase glucose rate of appearance and multiplied x 100.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验